Long-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerations

Overview of attention for article published in Therapeutics and Clinical Risk Management, September 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 29 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 3 publications that cite this research output.

3

The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.

An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1

Article in ERJ Open Research (October 2020)

Burden of Asthma and Role of 2.5 µg Tiotropium Respimat® as an Add-On Therapy: A Systematic Review of Phase 2/3 Trials

Article in Advances in Therapy (August 2019)

Paradigms in chronic obstructive pulmonary disease: phenotypes, immunobiology, and therapy with a focus on vascular disease

Article in Journal of Investigative Medicine (August 2017)